Mills left to focus on another CEO role, and the filing says his departure was not tied to a company disagreement. An independent director became chair, and Tassé remains on the board, with no business change reported.
This points to a board handoff, not a dispute over REGENXBIO’s work. An independent director became chair, and Daniel Tassé remains on the board. The filing reports no business change, so it does not change the company’s outlook.
Follow REGENXBIO Inc. (RGNX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RGNX